Access in all areas? A round up of developments in market access and health technology assessment: part 9
Key Points
Spain's pharmaceutical legislation reform aims to improve market access for new drugs.
France's approach to health economic evaluation has evolved to better assess treatment value.
The US proposes a Most Favored Nation pricing mechanism to lower drug costs.
These developments indicate a global trend towards enhancing market access and value assessment in healthcare.
Abstract
In this update, we examine Spain’s comprehensive pharmaceutical legislation reform; France’s refined health economic evaluation approach; and the US’ proposed Most Favored Nation pricing mechanism.